INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics

INmune Bio Inc. - Common stock (INMB): $12.72

0.18 (+1.44%)

POWR Rating

Component Grades













Add INMB to Watchlist
Sign Up

Industry: Biotech


of 476

in industry


  • Momentum is the dimension where INMB ranks best; there it ranks ahead of 39.4% of US stocks.
  • INMB's strongest trending metric is Stability; it's been moving down over the last 52 weeks.
  • INMB ranks lowest in Stability; there it ranks in the 2nd percentile.

INMB Stock Summary

  • INMB's price/sales ratio is 8,980.37; that's higher than the P/S ratio of 99.71% of US stocks.
  • With a year-over-year growth in debt of 9,203.19%, Inmune Bio Inc's debt growth rate surpasses 99.69% of about US stocks.
  • Revenue growth over the past 12 months for Inmune Bio Inc comes in at 128.25%, a number that bests 94.3% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Inmune Bio Inc, a group of peers worth examining would be MRSN, KROS, URG, ZOM, and BNTC.
  • Visit INMB's SEC page to see the company's official filings. To visit the company's web site, go to

INMB Valuation Summary

  • INMB's price/earnings ratio is -21.9; this is 160% lower than that of the median Healthcare stock.
  • Over the past 31 months, INMB's price/sales ratio has gone NA NA.
  • INMB's price/sales ratio has moved NA NA over the prior 31 months.

Below are key valuation metrics over time for INMB.

Stock Date P/S P/B P/E EV/EBIT
INMB 2021-08-31 38172.7 9.7 -21.9 -20.6
INMB 2021-08-30 36372.7 9.3 -20.9 -19.6
INMB 2021-08-27 32236.4 8.2 -18.5 -17.2
INMB 2021-08-26 31027.3 7.9 -17.8 -16.5
INMB 2021-08-25 30227.3 7.7 -17.4 -16.1
INMB 2021-08-24 31527.3 8.0 -18.1 -16.8

INMB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INMB has a Quality Grade of D, ranking ahead of 11.03% of graded US stocks.
  • INMB's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows INMB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 1 -3.952
2021-03-31 0 1 -15.163
2020-12-31 0 1 -22.264
2020-09-30 0 NA -21.947
2020-06-30 0 NA -15.048
2020-03-31 0 NA -9.777

INMB Price Target

For more insight on analysts targets of INMB, see our INMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.75 Average Broker Recommendation 1.38 (Strong Buy)

INMB Stock Price Chart Interactive Chart >

Price chart for INMB

INMB Price/Volume Stats

Current price $12.72 52-week high $30.37
Prev. close $12.54 52-week low $8.40
Day low $12.40 Volume 20,082
Day high $12.99 Avg. volume 345,151
50-day MA $17.24 Dividend yield N/A
200-day MA $16.31 Market Cap 226.96M

INmune Bio Inc. - Common stock (INMB) Company Bio

INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.

INMB Latest News Stream

Event/Time News Detail
Loading, please wait...

INMB Latest Social Stream

Loading social stream, please wait...

View Full INMB Social Stream

Latest INMB News From Around the Web

Below are the latest news stories about Inmune Bio Inc that investors may wish to consider to help them evaluate INMB as an investment opportunity.

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy,” stated Dr. Charles Nicolette, chief exec

Yahoo | November 15, 2021

INmune Bio (NASDAQ:INMB) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report issued on Thursday morning, reports. According to Zacks, INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The companys product platform consists of []

Dakota Financial News | November 14, 2021

How Much Of INmune Bio, Inc. (NASDAQ:INMB) Do Insiders Own?

If you want to know who really controls INmune Bio, Inc. ( NASDAQ:INMB ), then you'll have to look at the makeup of its...

Yahoo | November 8, 2021

Zacks: Brokerages Anticipate INmune Bio, Inc. (NASDAQ:INMB) Will Announce Earnings of -$0.55 Per Share

Equities analysts forecast that INmune Bio, Inc. (NASDAQ:INMB) will post earnings per share (EPS) of ($0.55) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for INmune Bios earnings. INmune Bio reported earnings per share of ($0.24) in the same quarter last year, which suggests a negative year-over-year growth rate []

Dakota Financial News | November 6, 2021

INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call Transcript

INmune Bio, Inc. (INMB) Q3 2021 Earnings Conference Call November 3, 2021 16:30 ET Company Participants David Moss - Co-Founder and Chief Financial Officer R. J. Tesi - Chief Executive Officer and Co-Founder Mark Lowdell - Chief Scientific Officer and Co-Founder C. J. Barnum - Head, Neuroscience Conference Call Participants...

SA Transcripts on Seeking Alpha | November 4, 2021

Read More 'INMB' Stories Here

INMB Price Returns

1-mo -30.83%
3-mo -46.71%
6-mo -4.86%
1-year 43.24%
3-year N/A
5-year N/A
YTD -26.13%
2020 196.90%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7722 seconds.